May 2026
📣 VC round data is live. Check it out!
Largest BioTech Public Companies in Ireland
Benchmark revenue and EBITDA valuation multiples for public comps like
GH Research, Uniphar, Prothena Corp., Malin Corporation and Iterum Therapeutics.
 | GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development. | $25 | +104% | $2B | $1B | - | (30.0x) | ||
| Uniphar PLC is a diversified healthcare service organization with activities in Ireland, the UK, and the Benelux. The business activities of the group function through the Commercial & Clinical division, which provides outsourced services, specifically sales, marketing, and multichannel account management to pharmaco-medical manufacturers, and distribution and support services to medical device manufacturers. The product Access division consists of two service offerings, being: On-Demand Access and Exclusive Access. Supply Chain and Retail division provides both pre-wholesale distribution and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals, and veterinary surgeons in Ireland. | $5 | -- | $1B | $2B | 0.5x | 11.5x | ||
| Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others. | $10 | +58% | $502M | $180M | 18.6x | (1.0x) | ||
| Malin Corporation PLC is a life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where it believes that life science and healthcare technologies will deliver transformative treatments for patients. | $9 | -2% | $39M | ($33M) | - | (95.2x) | ||
| Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections. | $0 | -94% | $3M | $26M | - | - | ||
| Median | $9 | +28% | $502M | $180M | 9.5x | (15.5x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.